Scarica l'app Stockscreener
0.36
8.17%
0.0272
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
(ONC) Market Dynamics and Trading Signals (ONC:CA) - news.stocktradersdaily.com
(ONC) Proactive Strategies (ONC:CA) - news.stocktradersdaily.com
Against the rise of early onset cancer: a Mugglehead roundup - Mugglehead Magazine
(ONC) Advanced Equity Analysis (ONC:CA) - news.stocktradersdaily.com
HC Wainwright Has Pessimistic Outlook of TSE:ONC Q2 Earnings - Defense World
Stocks In Play - Baystreet.ca
Q2 EPS Forecast for Oncolytics Biotech Reduced by Analyst - Defense World
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech Inc - MENAFN.com
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Dow slumps 460 points, or 1.1%, in early trading following Trump's latest tariff threats targeting Europe and Apple - The Globe and Mail
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - marketscreener.com
Oncolytics Biotech Inc. to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics (ONCY) Unveils Promising Phase I/II Clinical Trial Da - GuruFocus
Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities | ONCY Stock News - GuruFocus
Oncolytics Brief: Presenting New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - Nasdaq
HC Wainwright Issues Negative Outlook for TSE:ONC Earnings - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
(ONC) Strategic Market Analysis (ONC:CA) - news.stocktradersdaily.com
ONCY: Analyst Reiterates Buy Rating with $5.00 Price Target | ONCY Stock News - GuruFocus
Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Price Target at $4.33 - Defense World
Oncolytic Virus Therapy Market Detailed In New Research Report - openPR.com
Jones Trading Reaffirms “Hold” Rating for Oncolytics Biotech (NASDAQ:ONCY) - Defense World
Options Volatility and Implied Earnings Moves Today, May 16, 2025 - The Globe and Mail
(ONC) Market Performance Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech (ONCY) Downgraded by Jones Trading | ONCY Sto - GuruFocus
Oncolytics (ONCY) Downgraded Amid CEO Search and Capital Concerns | ONCY Stock News - GuruFocus
Oncolytics Biotech (ONCY) Downgraded by Jones Trading | ONCY Stock News - GuruFocus
Oncolytics Biotech’s Earnings Call: Optimism Amid Challenges - TipRanks
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Oncolytics Biotech Reports Q1 Results and Clinical Progress - TipRanks
Oncolytics Biotech Reports Q1 2025 Financial Results - TipRanks
Oncolytics Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oncolytics Biotech Reports Promising Q1 Results and Advances in Cancer Treatment - TipRanks
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum - marketscreener.com
How To Trade (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights - Kilgore News Herald
Oncolytics Biotech Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
(ONC) Trading Strategy and Analysis (ONC:CA) - news.stocktradersdaily.com
Off-market insider buying at Ansar Financial and Dev. (AFD) - The Globe and Mail
(ONC) Stock Analysis and Trading Signals (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14 - TipRanks
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Inc. - Baystreet.ca
Oncolytics Biotech to Discuss Q1 Financial Results and Operational Highlights - TipRanks
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ONCY Stock News - GuruFocus
(ONC) Risk-Controlled Trading Report (ONC:CA) - news.stocktradersdaily.com
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):